Recommendations on the use of 18F-FDG PET in oncology
Fletcher JW et al. - In a trial to develop recommendations on use of 18F-FDG PET in breast, colorectal, esophageal, head and neck, lung, pancreatic, and thyroid cancer; lymphoma, melanoma, and sarcoma; and unknown primary tumor, it was recommended that 18F-FDG PET should be used as an imaging tool in addition to conventional radiologic methods such as CT or MRI Methods- A search was performed to identify all published randomized controlled trials and systematic reviews in the literature
- An additional search was performed to identify relevant unpublished systematic reviews
- Publications comprised both retrospective and prospective studies of varied methodologic quality
- Anticipated consequences of false-positive and false-negative tests when evaluating clinical usefulness, and impact of 18F-FDG PET on management of cancer pts, were also reviewed
Results- 18F-FDG PET should be used as an imaging tool in addition to conventional radiologic methods such as CT or MRI
- Any positive finding that could lead to a clinically significant change in pt management should be confirmed by subsequent histopathologic examination because of the risk of false-positive results
- 18F-FDG PET should be used in the appropriate clinical setting for the diagnosis of head and neck, lung, or pancreatic cancer and for unknown primary tumor
[more...]
|
|
|
